HSE approves reimbursement of AJOVY®▼ (fremanezumab) in migraine

Teva Pharmaceuticals Ireland is delighted to announce the approval of AJOVY®(fremanezumab) 225mg pre-filled syringe for prescription under the High Tech Drug Payments Scheme, from October 1st 2021.

AJOVY is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. 01 From October 1st 2021, AJOVY® is reimbursed, under High Tech arrangements, for the prophylaxis of chronic migraine in adults who have failed three or more migraine-preventive treatments. Ajovy® offers the flexibility of monthly dosing (225 mg once monthly), or quarterly dosing (675 mg every three months) 01 and is the only anti-CGRP with the additional benefit of switching between the two. 01  

Between 12-15% of Irish people suffer from migraine – this means that roughly half a million people suffer from migraine in Ireland. 02 Migraine has an impact on almost every aspect of a patient’s life – a survey 03 carried out amongst 265 adult Migraine sufferers in Ireland revealed:

  • 53% of migraine suffers said that their partner is impacted 03
     
  • 57% said migraines impacted the ability to provide unconditional support to their children03
     
  • 41% of people with migraine said it impacted on the career 03

Dr Martin Ruttledge, Consultant Neurologist, Beaumont hospital said:

"There are approximately one million people in Ireland who experience some level of migraine, a sometimes underestimated and misunderstood complex neurological disorder. The financial and societal burden of migraine is significant. It is the third most common disease in the world and is ranked as the second most disabling non-fatal medical condition in women by the World Health Organization (WHO). People living with more chronic forms of migraine may be very disabled and frequently struggle to maintain a reasonable quality of life. The approval of fremanezumab (Ajovy) by the HSE is very much welcomed by the many patients who suffer from migraine and is a significant addition to the treatment options available to Neurologists and Headache Specialists who treat migraine."

Clodagh Kevans, Director, Specialty Medicines Ireland said:

“On behalf of Teva Pharmaceuticals Ireland, we are delighted to announce that the HSE has approved the use of AJOVY®▼ (fremanezumab) for the prophylaxis of chronic migraine in adults who have failed three or more migraine-preventive treatments. With over half a million people in Ireland suffering migraines, combined with the hugely disabling effects of migraines, this news represents a major step forward in offering migraine sufferers a much needed, and much anticipated, treatment option. At Teva we are committed to supporting people affected by migraine, and giving their treating healthcare professional, innovative treatment options.”

More information on AJOVY® (fremanezumab) can be found at Ajovy.ie

About Teva Ireland: For more information on Teva please visit www.teva.ie

About AJOVY® (fremanezumab): For more information on AJOVY® please visit www.Ajovy.ie

About Beyond Migraine Survey in Ireland: For more information please visit https://www.teva.ie/patients/beyond-migraine/

About migraine, from the Migraine Association of Ireland: For more information please visit https://migraine.ie/


References

  1. Back to contents.

    AJOVY 225 mg solution for injection - Summary of Product Characteristics.

  2. Back to contents.
  3. Back to contents.

    Teva / Beyond Migraine – The Real You research results. Research conducted by Empathy Research. Prepared October 2020.

Date of preparation: December 2021
Reference: COB-IE-NP-00078

You might also be interested in